PMID- 10396705
OWN - NLM
STAT- MEDLINE
DCOM- 19990823
LR  - 20131121
IS  - 0914-5087 (Print)
IS  - 0914-5087 (Linking)
VI  - 33
IP  - 6
DP  - 1999 Jun
TI  - Effects of long-term treatment with pimobendan on neurohumoral factors in 
      patients with non-ischemic chronic moderate heart failure.
PG  - 317-25
AB  - To evaluate the effects of the addition of pimobendan to an optimal basic regimen 
      on plasma levels of neurohumoral factors in patients with non-ischemic, moderate 
      heart failure during 2-year follow-up. This prospective, observational study 
      involved 16 patients with non-ischemic, moderate heart failure [New York Heart 
      Association (NYHA) functional class IIM-III] receiving an optimal basic regimen 
      of digitalis, diuretics and angiotensin-converting enzyme inhibitor. Eight 
      patients (Group P) were also administered pimobendan at a dose of 2.5 or 5 mg 
      daily, while the other 8 served as controls (Group C). After 3 months of 
      pimobendan administration, the plasma levels of norepinephrine and atrial 
      natriuretic peptide and brain natriuretic peptide decreased and left ventricular 
      ejection fraction improved. After 1 year, the cardiac symptoms, assessed using 
      the Specific Activity Scale as well as the NYHA functional class, improved and 
      the left ventricular end-diastolic diameter decreased. These improvements in 
      Group P were maintained for 2 years. However, in Group C, the cardiac symptoms 
      and the neurohumoral factor levels remained unchanged or deteriorated during this 
      study, and one patient died of heart failure. Long-term combination therapy with 
      the optimal basic regimen and pimobendan has potentially beneficial effects on 
      neurohumoral factor levels and cardiac symptoms in patients with non-ischemic, 
      chronic moderate heart failure.
FAU - Sasaki, T
AU  - Sasaki T
AD  - Division of Cardiology, Osaka Dai-ichi Hospital.
FAU - Kubo, T
AU  - Kubo T
FAU - Komamura, K
AU  - Komamura K
FAU - Nishikimi, T
AU  - Nishikimi T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Neurotransmitter Agents)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Pyridazines)
RN  - 0 (Vasodilator Agents)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 34AP3BBP9T (pimobendan)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Atrial Natriuretic Factor/blood
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Neurotransmitter Agents/*blood
MH  - Norepinephrine/blood
MH  - Phosphodiesterase Inhibitors/*administration & dosage
MH  - Prospective Studies
MH  - Pyridazines/*administration & dosage
MH  - Stroke Volume/drug effects
MH  - Vasodilator Agents/*administration & dosage
EDAT- 1999/07/09 00:00
MHDA- 1999/07/09 00:01
CRDT- 1999/07/09 00:00
PHST- 1999/07/09 00:00 [pubmed]
PHST- 1999/07/09 00:01 [medline]
PHST- 1999/07/09 00:00 [entrez]
PST - ppublish
SO  - J Cardiol. 1999 Jun;33(6):317-25.